文献速递肾小球疾病

多中心临床研究与人性化小鼠模型提示肾小球系膜IgA2沉积参与IgA肾病发病

Evidence from multicenter clinical studies and humanized mouse models indicates that glomerular mesangial IgA2 deposition contributes to the pathogenesis of IgA nephropathy.
PubMed 文献 · Kidney Int · 2026-03-14

研究通过激光捕获显微切割联合质谱(LCM/MS)分析14例IgA肾病患者和10例健康供肾活检组织,并在三个中国临床中心对161例活检证实的IgA肾病病例进行多中心免疫荧光分析,同时构建人性化IgA1/IgA2小鼠模型诱导IgA肾病。结果显示超过98%的IgA肾病病例存在系膜IgA2沉积,其强度与慢性病变(牛津T病变)和肾功能障碍显著相关,人性化IgA2小鼠出现肾小管萎缩和更强的补体C3激活及间质巨噬细胞浸润。结论提示IgA2参与IgA肾病发病,应纳入未来研究。

要点

  • 超过98%的IgA肾病病例存在系膜IgA2沉积,且强度与慢性病变和肾功能障碍相关。
  • 人性化IgA2小鼠出现肾小管萎缩、更强的肾小球补体C3激活和间质巨噬细胞浸润。
  • IgA2应被纳入未来IgA肾病发病机制研究,超越以IgA1为中心的模式。

核心结论

  • IgA2能够沉积于肾小球系膜、激活补体并诱导独特的组织病理学损伤模式,参与IgA肾病发病。

研究设计与样本

  • 对14例IgA肾病患者和10例健康供肾活检组织进行LCM/MS分析。
  • 在三个中国临床中心对161例活检证实的IgA肾病病例进行多中心免疫荧光分析。
  • 构建人性化IgA1/IgA2小鼠模型,腹腔注射干酪乳杆菌细胞壁提取物加完全弗氏佐剂诱导IgA肾病。

主要发现

  • LCM/MS在IgA肾病肾小球中检测到IgA2(m1)和IgA2(m2),证实IgA2沉积但丰度低于IgA1。
  • 多中心免疫荧光显示超过98%的IgA肾病病例存在系膜IgA2,强度与牛津T病变相关(ρ=0.237)。
  • 系膜IgA2强度与eGFR显著负相关(r=-0.272)。
  • 人性化IgA2小鼠出现肾小管萎缩(面积16%-22%),而人性化IgA1小鼠无此表现。
  • 与IgA1小鼠相比,IgA2小鼠肾小球补体C3激活更强且间质巨噬细胞浸润更明显。

临床怎么用

  • 肾内科医生应关注IgA2在IgA肾病中的潜在致病作用,未来研究可纳入IgA2相关指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: While IgA1 is well established as pathogenic in IgA nephropathy (IgAN), IgA2's role remains controversial. The most notable difference between IgA1 and IgA2 lies in the hinge region: IgA2 lacks a 13-amino acid segment unique in IgA1, which contains nine serine and threonine residues that can be O-glycosylated. Here, we investigated the role of IgA2 in the development of IgAN. METHODS: To characterize glomerular IgA2 deposition in IgAN, we performed laser capture microdissection coupled with mass spectrometry (LCM/MS) on kidney biopsies from 14 patients with IgAN and 10 healthy donors. Additionally, multicenter immunofluorescence analysis was conducted using validated subclass-specific antibodies on 161 biopsy-proven IgAN cases from three Chinese clinical centers. To establish IgA2's pathogenicity, we generated humanized IgA1/IgA2 mouse models and induced IgAN via intraperitoneal administration of Lactobacillus casei cell wall extract with complete Freund's adjuvant. RESULTS: LCM/MS detected both IgA2(m1) and IgA2(m2) in IgAN glomeruli, confirming IgA2 deposition despite lower abundance than IgA1. Multicenter kidney immunofluorescence staining revealed mesangial IgA2 in over 98% of IgAN cases, with significant intensity correlating with chronic lesions (Oxford T lesion: ρ of 0.237) and significant kidney dysfunction (eGFR: r of -0.272). The humanized IgA2 model exhibited IgA2 mesangial deposition and developed tubular atrophy (16%-22% area), absent in humanized IgA1 mice. IgA2 mice also exhibited stronger glomerular complement C3 activation and interstitial macrophage infiltration compared with IgA1 mice. CONCLUSIONS: Our study highlights the role of IgA2 in IgAN development, demonstrating its capacity for glomerular deposition, complement activation, and induction of distinct histopathological injury patterns. These findings extend the IgA1-centric paradigm, indicating that IgA2 should be incorporated into future investigations of IgAN.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Li R, Ma Y, Xie X, et al. Evidence from multicenter clinical studies and humanized mouse models indicates that glomerular mesangial IgA2 deposition contributes to the pathogenesis of IgA nephropathy. Kidney Int. 2026. PMID: 41833637. doi:10.1016/j.kint.2026.02.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。